,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4d2AH'}, 'Id': 'a0POZ00000EZA4d2AH', 'Event_Date__c': '2020-05-25', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BwV3QAK'}, 'change': None}]",May 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2020', 'fs': 'Jul 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4e2AH'}, 'Id': 'a0POZ00000EZA4e2AH', 'Event_Date__c': '2020-07-10', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2020', 'Status_History__c': 'a132P000000BwV8QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4f2AH'}, 'Id': 'a0POZ00000EZA4f2AH', 'Event_Date__c': '2020-09-21', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CBZVQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4g2AH'}, 'Id': 'a0POZ00000EZA4g2AH', 'Event_Date__c': '2020-09-22', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CBnEQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib be funded for the first-line treatment of unresectable hepatocellular carcinoma with a <b>low priority</b> within the context of treatments for malignancies, subject to the following Special Authority criteria:</p><p><span style=""font-size: 9pt;"">Initial application – (hepatocellular carcinoma) only from an oncologist or gastroenterologist or hepatologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 The patient has systemic-treatment-naïve, advanced or intermediate (unresectable), Barcelona Clinic Liver Cancer Stage B or C Hepatocellular carcinoma; and</span></p><p><span style=""font-size: 9pt;"">2 The patient has preserved liver function (Childs Pugh A); and</span></p><p><span style=""font-size: 9pt;"">3 The patient has good performance status (ECOG ≤ 2); and</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa04 Patient must not be suitable for Trans arterial Chemoembolisation (TACE)</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><span style=""font-size: 9pt;"">Renewal – (hepatocellular carcinoma) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">Both:</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa01 No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa02 The treatment remains appropriate and the patient is benefitting from treatment </span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making its recommendation, the Subcommittee considered the unmet need for effective treatment options for patients with unresectable hepatocellular carcinoma and, the relatively high incidence of this disease in Māori and Pacific people, together with the low quality, low strength evidence of benefit from lenvatinib.\xa0\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib be funded for the first-line treatment of unresectable hepatocellular carcinoma with a <b>low priority</b> within the context of treatments for malignancies, subject to the following Special Authority criteria:</p><p><span style=""font-size: 9pt;"">Initial application – (hepatocellular carcinoma) only from an oncologist or gastroenterologist or hepatologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 The patient has systemic-treatment-naïve, advanced or intermediate (unresectable), Barcelona Clinic Liver Cancer Stage B or C Hepatocellular carcinoma; and</span></p><p><span style=""font-size: 9pt;"">2 The patient has preserved liver function (Childs Pugh A); and</span></p><p><span style=""font-size: 9pt;"">3 The patient has good performance status (ECOG ≤ 2); and</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa04 Patient must not be suitable for Trans arterial Chemoembolisation (TACE)</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><span style=""font-size: 9pt;"">Renewal – (hepatocellular carcinoma) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">Both:</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa01 No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa02 The treatment remains appropriate and the patient is benefitting from treatment </span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making its recommendation, the Subcommittee considered the unmet need for effective treatment options for patients with unresectable hepatocellular carcinoma and, the relatively high incidence of this disease in Māori and Pacific people, together with the low quality, low strength evidence of benefit from lenvatinib.\xa0\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted hepatocellular carcinoma makes up approximately 90% of all liver cancers and is predominantly associated with chronic liver disease, most commonly cirrhosis. The Subcommittee noted that common causes of cirrhosis include hepatitis B, hepatitis C, heavy alcohol consumption, diabetes mellitus, obesity, and haemochromatosis. The Subcommittee noted that hepatocellular carcinoma is often diagnosed at an advanced stage and that patients with advanced hepatocellular carcinoma have a poor quality of life, with a five-year survival of 7% and median survival of 7 months. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Māori are disproportionately affected by liver cancer, making up 23% of registrations and have a reported 3-5 times higher age-standardised rate of liver cancer compared to non-Māori (<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>Ministry of Health. 2019</b></a><span style=""font-size: 12pt; font-family: Arial, sans-serif;"">; </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24892150/"" target=""_blank"" style=""font-size: 12pt;""><b>Chamberlain et al. Aust NZ J Pub Heal. 2013;37:520-6</b></a>).<b> </b>The Subcommittee noted that Pacific people also have a higher age-standardised rate of liver cancer compared to European/other New Zealanders (<a href=""https://www.otago.ac.nz/wellington/otago036828.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Meredith et al. Canc Caus Contr. 2012;23:1173-84</b></a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that viral hepatitis increases the risk of developing hepatocellular carcinoma, and considered that rates of this risk factor are likely to decline over time. The Subcommittee considered that rates of metabolic syndrome and non-alcoholic steatohepatitis (NASH) are likely to increase over time and associated with the risk of hepatocellular carcinoma. The Subcommittee considered that these risk factors may disproportionately effect groups of people currently experiencing disparities in access to healthcare. </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently no funded, targeted pharmacological treatments for the first line treatment of unresectable hepatocellular carcinoma. The Subcommittee noted that current treatments include radical therapy (such as surgery, liver transplant or radiofrequency ablation), for patients with early stage disease (Barcelona Clinic Liver Cancer (BCLC) 0 or A), trans arterial chemoembolisation (TACE) for patients with intermediate stage disease (BCLC B), and best supportive care for patients with BCLC B stage disease that is unsuitable for TACE, and\xa0end stage disease (BCLC C and D). The Subcommittee considered that there is disparity in access to TACE around the country. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the randomised, open-label, phase III, multicentre, non-inferiority REFLECT trial, which investigated the use of oral lenvatinib compared with sorafenib in patients with unresectable hepatocellular carcinoma (<a href=""https://pubmed.ncbi.nlm.nih.gov/29433850/"" target=""_blank"" style=""font-size: 12pt;""><b>Kudo et al. Lancet. 2018;391:1163-73</b></a>). The Subcommittee noted that no statistically significant difference in overall survival was observed between the lenvatinib group and sorafenib group, hazard ratio (HR) 0·92, 95% confidence interval (CI): 0·79–1·06. The Subcommittee noted that significant differences, favouring lenvatinib, were observed between groups in the secondary outcomes of median progression free survival (HR 0·66, 95% CI: 0·57−0·77, p&lt;0·0001), median time to progression (HR 0·63, 95% CI: 0·53–0·73, p&lt;0·0001) and objective response rate (odds ratio 3·13, 95% CI: 2·15–4·56, p&lt;0·0001). The Subcommittee considered that the strength and quality of the evidence of lenvatinib for hepatocellular carcinoma was low. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the frequency of adverse events reported in the REFLECT trial was similar between lenvatinib and sorafenib treated groups. </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that an application for sorafenib for advanced hepatocellular carcinoma had previously been assessed by PTAC and its Subcommittees, most recently receiving a decline recommendation from CaTSoP due to limited clinically meaningful benefit and the associated high expense given this limited benefit (more information regarding sorafenib can be found <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu69/p000603"" target=""_blank"" style=""font-size: 12pt;""><b>here</b></a>). </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that as there are currently no funded targeted pharmacological treatments for unresectable hepatocellular carcinoma, the appropriate comparator for lenvatinib in this indication is best supportive care, including TACE. The Subcommittee noted that there is currently no published randomised evidence comparing lenvatinib with placebo and considered that it is unlikely such evidence would be published. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a covariate adjustment<i> </i>provided by the supplier which indirectly compared lenvatinib and placebo, using the sorafenib vs placebo SHARP and ASIA-PAC trials (<a href=""https://pubmed.ncbi.nlm.nih.gov/18650514/"" target=""_blank"" style=""font-size: 12pt;""><b>Llovet et al. N Eng J Med. 2008;359:378-90</b></a><b>, </b><a href=""https://pubmed.ncbi.nlm.nih.gov/19095497/"" target=""_blank"" style=""font-size: 12pt;""><b>Cheng et al. Lancet Oncol. 2009;10:25-34</b></a>), and the lenvatinib vs sorafenib REFLECT trial. The Subcommittee noted the results of this indirect analysis indicated that compared with placebo, lenvatinib showed a general trend toward greater efficacy: HR for overall survival of 0.63 (95% CI: 0.50-0.80), progression free survival 0.38 (95% CI: 0.30-0.49), and objective response rate of 56.49 (95% CI: 4.53-704.99). The Subcommittee noted that the full methodology of this comparison was not received and as such was not reviewed by the Subcommittee.\xa0</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the prevalent pool of hepatocellular carcinoma patients is small due to the short median survival of patients. The Subcommittee therefore considered that the prevalent pool of patients that would require treatment would be minimal in addition to the incident patients if lenvatinib were funded in this indication. </p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the supplier assumed in its analysis that the incidence of liver cancer would decline over time due to the increased availability of hepatitis C treatments; however, the Subcommittee considered that it would likely remain constant, noting the increasing prevalence of metabolic syndrome and NASH with hepatic sequelae including hepatocellular carcinoma.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered under the proposed Special Authority criteria, approximately 60-70 patients would be treated with lenvatinib each year. The Subcommittee considered that if lenvatinib were funded in this indication, it would be appropriate to assume an uptake rate of 90%. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, should lenvatinib be funded in this indication then it may be used as a bridge to liver transplantation, and considered that PHARMAC could seek further advice on this from transplantation clinicians. The Subcommittee considered that, should lenvatinib be funded for this indication then there may be a modest increase in health resource required to manage adverse events, largely use of loperamide to manage diarrhoea.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is emerging evidence for atezolizumab and bevacizumab in this indication and that it would be interested to review data for additional classes of medicines, given the unmet need in this patient group.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted hepatocellular carcinoma makes up approximately 90% of all liver cancers and is predominantly associated with chronic liver disease, most commonly cirrhosis. The Subcommittee noted that common causes of cirrhosis include hepatitis B, hepatitis C, heavy alcohol consumption, diabetes mellitus, obesity, and haemochromatosis. The Subcommittee noted that hepatocellular carcinoma is often diagnosed at an advanced stage and that patients with advanced hepatocellular carcinoma have a poor quality of life, with a five-year survival of 7% and median survival of 7 months. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Māori are disproportionately affected by liver cancer, making up 23% of registrations and have a reported 3-5 times higher age-standardised rate of liver cancer compared to non-Māori (<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>Ministry of Health. 2019</b></a><span style=""font-size: 12pt; font-family: Arial, sans-serif;"">; </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24892150/"" target=""_blank"" style=""font-size: 12pt;""><b>Chamberlain et al. Aust NZ J Pub Heal. 2013;37:520-6</b></a>).<b> </b>The Subcommittee noted that Pacific people also have a higher age-standardised rate of liver cancer compared to European/other New Zealanders (<a href=""https://www.otago.ac.nz/wellington/otago036828.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Meredith et al. Canc Caus Contr. 2012;23:1173-84</b></a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that viral hepatitis increases the risk of developing hepatocellular carcinoma, and considered that rates of this risk factor are likely to decline over time. The Subcommittee considered that rates of metabolic syndrome and non-alcoholic steatohepatitis (NASH) are likely to increase over time and associated with the risk of hepatocellular carcinoma. The Subcommittee considered that these risk factors may disproportionately effect groups of people currently experiencing disparities in access to healthcare. </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently no funded, targeted pharmacological treatments for the first line treatment of unresectable hepatocellular carcinoma. The Subcommittee noted that current treatments include radical therapy (such as surgery, liver transplant or radiofrequency ablation), for patients with early stage disease (Barcelona Clinic Liver Cancer (BCLC) 0 or A), trans arterial chemoembolisation (TACE) for patients with intermediate stage disease (BCLC B), and best supportive care for patients with BCLC B stage disease that is unsuitable for TACE, and\xa0end stage disease (BCLC C and D). The Subcommittee considered that there is disparity in access to TACE around the country. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the randomised, open-label, phase III, multicentre, non-inferiority REFLECT trial, which investigated the use of oral lenvatinib compared with sorafenib in patients with unresectable hepatocellular carcinoma (<a href=""https://pubmed.ncbi.nlm.nih.gov/29433850/"" target=""_blank"" style=""font-size: 12pt;""><b>Kudo et al. Lancet. 2018;391:1163-73</b></a>). The Subcommittee noted that no statistically significant difference in overall survival was observed between the lenvatinib group and sorafenib group, hazard ratio (HR) 0·92, 95% confidence interval (CI): 0·79–1·06. The Subcommittee noted that significant differences, favouring lenvatinib, were observed between groups in the secondary outcomes of median progression free survival (HR 0·66, 95% CI: 0·57−0·77, p&lt;0·0001), median time to progression (HR 0·63, 95% CI: 0·53–0·73, p&lt;0·0001) and objective response rate (odds ratio 3·13, 95% CI: 2·15–4·56, p&lt;0·0001). The Subcommittee considered that the strength and quality of the evidence of lenvatinib for hepatocellular carcinoma was low. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the frequency of adverse events reported in the REFLECT trial was similar between lenvatinib and sorafenib treated groups. </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that an application for sorafenib for advanced hepatocellular carcinoma had previously been assessed by PTAC and its Subcommittees, most recently receiving a decline recommendation from CaTSoP due to limited clinically meaningful benefit and the associated high expense given this limited benefit (more information regarding sorafenib can be found <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu69/p000603"" target=""_blank"" style=""font-size: 12pt;""><b>here</b></a>). </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that as there are currently no funded targeted pharmacological treatments for unresectable hepatocellular carcinoma, the appropriate comparator for lenvatinib in this indication is best supportive care, including TACE. The Subcommittee noted that there is currently no published randomised evidence comparing lenvatinib with placebo and considered that it is unlikely such evidence would be published. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a covariate adjustment<i> </i>provided by the supplier which indirectly compared lenvatinib and placebo, using the sorafenib vs placebo SHARP and ASIA-PAC trials (<a href=""https://pubmed.ncbi.nlm.nih.gov/18650514/"" target=""_blank"" style=""font-size: 12pt;""><b>Llovet et al. N Eng J Med. 2008;359:378-90</b></a><b>, </b><a href=""https://pubmed.ncbi.nlm.nih.gov/19095497/"" target=""_blank"" style=""font-size: 12pt;""><b>Cheng et al. Lancet Oncol. 2009;10:25-34</b></a>), and the lenvatinib vs sorafenib REFLECT trial. The Subcommittee noted the results of this indirect analysis indicated that compared with placebo, lenvatinib showed a general trend toward greater efficacy: HR for overall survival of 0.63 (95% CI: 0.50-0.80), progression free survival 0.38 (95% CI: 0.30-0.49), and objective response rate of 56.49 (95% CI: 4.53-704.99). The Subcommittee noted that the full methodology of this comparison was not received and as such was not reviewed by the Subcommittee.\xa0</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the prevalent pool of hepatocellular carcinoma patients is small due to the short median survival of patients. The Subcommittee therefore considered that the prevalent pool of patients that would require treatment would be minimal in addition to the incident patients if lenvatinib were funded in this indication. </p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the supplier assumed in its analysis that the incidence of liver cancer would decline over time due to the increased availability of hepatitis C treatments; however, the Subcommittee considered that it would likely remain constant, noting the increasing prevalence of metabolic syndrome and NASH with hepatic sequelae including hepatocellular carcinoma.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered under the proposed Special Authority criteria, approximately 60-70 patients would be treated with lenvatinib each year. The Subcommittee considered that if lenvatinib were funded in this indication, it would be appropriate to assume an uptake rate of 90%. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, should lenvatinib be funded in this indication then it may be used as a bridge to liver transplantation, and considered that PHARMAC could seek further advice on this from transplantation clinicians. The Subcommittee considered that, should lenvatinib be funded for this indication then there may be a modest increase in health resource required to manage adverse events, largely use of loperamide to manage diarrhoea.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is emerging evidence for atezolizumab and bevacizumab in this indication and that it would be interested to review data for additional classes of medicines, given the unmet need in this patient group.</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item. \xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item. \xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4h2AH'}, 'Id': 'a0POZ00000EZA4h2AH', 'Event_Date__c': '2021-02-25', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Feb 2021', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib be funded for the first-line treatment of unresectable hepatocellular carcinoma with a <b>low priority</b> within the context of treatments for malignancies, subject to the following Special Authority criteria:</p><p><span style=""font-size: 9pt;"">Initial application – (hepatocellular carcinoma) only from an oncologist or gastroenterologist or hepatologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 The patient has systemic-treatment-naïve, advanced or intermediate (unresectable), Barcelona Clinic Liver Cancer Stage B or C Hepatocellular carcinoma; and</span></p><p><span style=""font-size: 9pt;"">2 The patient has preserved liver function (Childs Pugh A); and</span></p><p><span style=""font-size: 9pt;"">3 The patient has good performance status (ECOG ≤ 2); and</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa04 Patient must not be suitable for Trans arterial Chemoembolisation (TACE)</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><span style=""font-size: 9pt;"">Renewal – (hepatocellular carcinoma) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">Both:</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa01 No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">\xa0\xa0\xa02 The treatment remains appropriate and the patient is benefitting from treatment </span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making its recommendation, the Subcommittee considered the unmet need for effective treatment options for patients with unresectable hepatocellular carcinoma and, the relatively high incidence of this disease in Māori and Pacific people, together with the low quality, low strength evidence of benefit from lenvatinib.\xa0\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item. \xa0</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted hepatocellular carcinoma makes up approximately 90% of all liver cancers and is predominantly associated with chronic liver disease, most commonly cirrhosis. The Subcommittee noted that common causes of cirrhosis include hepatitis B, hepatitis C, heavy alcohol consumption, diabetes mellitus, obesity, and haemochromatosis. The Subcommittee noted that hepatocellular carcinoma is often diagnosed at an advanced stage and that patients with advanced hepatocellular carcinoma have a poor quality of life, with a five-year survival of 7% and median survival of 7 months. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that Māori are disproportionately affected by liver cancer, making up 23% of registrations and have a reported 3-5 times higher age-standardised rate of liver cancer compared to non-Māori (<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>Ministry of Health. 2019</b></a><span style=""font-size: 12pt; font-family: Arial, sans-serif;"">; </span><a href=""https://pubmed.ncbi.nlm.nih.gov/24892150/"" target=""_blank"" style=""font-size: 12pt;""><b>Chamberlain et al. Aust NZ J Pub Heal. 2013;37:520-6</b></a>).<b> </b>The Subcommittee noted that Pacific people also have a higher age-standardised rate of liver cancer compared to European/other New Zealanders (<a href=""https://www.otago.ac.nz/wellington/otago036828.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Meredith et al. Canc Caus Contr. 2012;23:1173-84</b></a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that viral hepatitis increases the risk of developing hepatocellular carcinoma, and considered that rates of this risk factor are likely to decline over time. The Subcommittee considered that rates of metabolic syndrome and non-alcoholic steatohepatitis (NASH) are likely to increase over time and associated with the risk of hepatocellular carcinoma. The Subcommittee considered that these risk factors may disproportionately effect groups of people currently experiencing disparities in access to healthcare. </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently no funded, targeted pharmacological treatments for the first line treatment of unresectable hepatocellular carcinoma. The Subcommittee noted that current treatments include radical therapy (such as surgery, liver transplant or radiofrequency ablation), for patients with early stage disease (Barcelona Clinic Liver Cancer (BCLC) 0 or A), trans arterial chemoembolisation (TACE) for patients with intermediate stage disease (BCLC B), and best supportive care for patients with BCLC B stage disease that is unsuitable for TACE, and\xa0end stage disease (BCLC C and D). The Subcommittee considered that there is disparity in access to TACE around the country. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the results of the randomised, open-label, phase III, multicentre, non-inferiority REFLECT trial, which investigated the use of oral lenvatinib compared with sorafenib in patients with unresectable hepatocellular carcinoma (<a href=""https://pubmed.ncbi.nlm.nih.gov/29433850/"" target=""_blank"" style=""font-size: 12pt;""><b>Kudo et al. Lancet. 2018;391:1163-73</b></a>). The Subcommittee noted that no statistically significant difference in overall survival was observed between the lenvatinib group and sorafenib group, hazard ratio (HR) 0·92, 95% confidence interval (CI): 0·79–1·06. The Subcommittee noted that significant differences, favouring lenvatinib, were observed between groups in the secondary outcomes of median progression free survival (HR 0·66, 95% CI: 0·57−0·77, p&lt;0·0001), median time to progression (HR 0·63, 95% CI: 0·53–0·73, p&lt;0·0001) and objective response rate (odds ratio 3·13, 95% CI: 2·15–4·56, p&lt;0·0001). The Subcommittee considered that the strength and quality of the evidence of lenvatinib for hepatocellular carcinoma was low. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the frequency of adverse events reported in the REFLECT trial was similar between lenvatinib and sorafenib treated groups. </p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that an application for sorafenib for advanced hepatocellular carcinoma had previously been assessed by PTAC and its Subcommittees, most recently receiving a decline recommendation from CaTSoP due to limited clinically meaningful benefit and the associated high expense given this limited benefit (more information regarding sorafenib can be found <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pu69/p000603"" target=""_blank"" style=""font-size: 12pt;""><b>here</b></a>). </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that as there are currently no funded targeted pharmacological treatments for unresectable hepatocellular carcinoma, the appropriate comparator for lenvatinib in this indication is best supportive care, including TACE. The Subcommittee noted that there is currently no published randomised evidence comparing lenvatinib with placebo and considered that it is unlikely such evidence would be published. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a covariate adjustment<i> </i>provided by the supplier which indirectly compared lenvatinib and placebo, using the sorafenib vs placebo SHARP and ASIA-PAC trials (<a href=""https://pubmed.ncbi.nlm.nih.gov/18650514/"" target=""_blank"" style=""font-size: 12pt;""><b>Llovet et al. N Eng J Med. 2008;359:378-90</b></a><b>, </b><a href=""https://pubmed.ncbi.nlm.nih.gov/19095497/"" target=""_blank"" style=""font-size: 12pt;""><b>Cheng et al. Lancet Oncol. 2009;10:25-34</b></a>), and the lenvatinib vs sorafenib REFLECT trial. The Subcommittee noted the results of this indirect analysis indicated that compared with placebo, lenvatinib showed a general trend toward greater efficacy: HR for overall survival of 0.63 (95% CI: 0.50-0.80), progression free survival 0.38 (95% CI: 0.30-0.49), and objective response rate of 56.49 (95% CI: 4.53-704.99). The Subcommittee noted that the full methodology of this comparison was not received and as such was not reviewed by the Subcommittee.\xa0</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the prevalent pool of hepatocellular carcinoma patients is small due to the short median survival of patients. The Subcommittee therefore considered that the prevalent pool of patients that would require treatment would be minimal in addition to the incident patients if lenvatinib were funded in this indication. </p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the supplier assumed in its analysis that the incidence of liver cancer would decline over time due to the increased availability of hepatitis C treatments; however, the Subcommittee considered that it would likely remain constant, noting the increasing prevalence of metabolic syndrome and NASH with hepatic sequelae including hepatocellular carcinoma.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered under the proposed Special Authority criteria, approximately 60-70 patients would be treated with lenvatinib each year. The Subcommittee considered that if lenvatinib were funded in this indication, it would be appropriate to assume an uptake rate of 90%. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, should lenvatinib be funded in this indication then it may be used as a bridge to liver transplantation, and considered that PHARMAC could seek further advice on this from transplantation clinicians. The Subcommittee considered that, should lenvatinib be funded for this indication then there may be a modest increase in health resource required to manage adverse events, largely use of loperamide to manage diarrhoea.</p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is emerging evidence for atezolizumab and bevacizumab in this indication and that it would be interested to review data for additional classes of medicines, given the unmet need in this patient group.</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'Status_History__c': 'a132P000000CdHIQA0'}, 'change': None}]",Jul 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4i2AH'}, 'Id': 'a0POZ00000EZA4i2AH', 'Event_Date__c': '2021-03-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CifbQAC'}, 'change': None}]",Mar 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2021', 'fs': 'Oct 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4j2AH'}, 'Id': 'a0POZ00000EZA4j2AH', 'Event_Date__c': '2021-10-26', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Oct 2021', 'Status_History__c': 'a132P000000DGwAQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4k2AH'}, 'Id': 'a0POZ00000EZA4k2AH', 'Event_Date__c': '2022-03-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DaPzQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4l2AH'}, 'Id': 'a0POZ00000EZA4l2AH', 'Event_Date__c': '2023-03-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a132P000000EDT5QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4m2AH'}, 'Id': 'a0POZ00000EZA4m2AH', 'Event_Date__c': '2023-12-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004JtL8YAK'}, 'change': None}]",Oct 2021,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4n2AH'}, 'Id': 'a0POZ00000EZA4n2AH', 'Event_Date__c': '2024-09-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EMReFYAX'}, 'change': None}]",Sep 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4o2AH'}, 'Id': 'a0POZ00000EZA4o2AH', 'Event_Date__c': '2024-10-04', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000Ez3XEYAZ'}, 'change': None}]",Oct 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZA4p2AH'}, 'Id': 'a0POZ00000EZA4p2AH', 'Event_Date__c': '2024-11-06', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000GGZYbYAP'}, 'change': None}]",Nov 2024,False,True
